
Opinion|Videos|August 16, 2024
The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Advertisement
Episodes in this series

- How do androgen receptor-targeted therapies, including abiraterone and enzalutamide, fit into the treatment paradigm, and when might you choose an androgen receptor-targeted therapy over other treatment options, or vice versa?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
3
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5










